Gold Nanoparticle Ophthalmic Composition for Contact Lens Comfort

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Contact lenses can cause corneal hypoxia, dehydration, and eye discomfort due to prolonged wear, especially in air-conditioned environments, and existing eye health products cannot effectively deliver antioxidative ingredients directly to the eye surface to prevent free radical damage and inflammation.

Innovation Solution

An ophthalmic product with an antioxidative function, comprising gold nanoparticles and at least one antioxidative auxiliary ingredient, such as β-carotene or L-ascorbic acid, in a concentration range of 0.01 ppm to 3000 ppm, which is surface-modified with functional molecular groups to enhance its effectiveness and safety for direct application to the eye surface.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If contact lenses are worn for prolonged periods, then user convenience and aesthetics are improved, but corneal hypoxia and dehydration occur causing eye injury and discomfort

Engineering Contradiction:
Improveuser convenienceVSAvoidcorneal hypoxia and dehydration
Core Design Contradiction:
Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The patent introduces an ophthalmic composition as an intermediary substance that contains antioxidative ingredients and growth factors. This composition is applied to the contact lens surface or directly to the eye to mediate between the contact lens and the cornea, providing protective effects against hypoxia and dehydration while maintaining the convenience of contact lens wear.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the chemical composition parameters of the ophthalmic product by incorporating specific antioxidative ingredients (such as vitamin C, vitamin E, lutein) and growth factors at controlled concentrations. These parameter changes enable the product to provide antioxidative protection and promote corneal epithelial cell regeneration, counteracting the harmful effects of prolonged contact lens wear.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If antioxidative ingredients are ingested, then systemic antioxidative protection is improved, but direct supply to the eye surface area cannot be achieved

Engineering Contradiction:
Improveantioxidative protectionVSAvoiddirect supply to eye surface
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The patent uses an ophthalmic composition as a mediator that delivers antioxidative ingredients directly to the eye surface area. This bypasses the limitation of systemic ingestion by providing a localized delivery system that ensures high concentrations of antioxidative substances reach the target site (eye surface) directly, achieving both reliable antioxidative protection and direct supply.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the digestive and circulatory system mechanism (ingestion and systemic distribution) with a direct topical application mechanism. By substituting the indirect systemic delivery route with direct local application, the patent achieves both reliable antioxidative effect and direct supply to the eye surface simultaneously.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

3Use of energy by moving object

If free radicals are generated from internal and external factors, then metabolic processes are improved, but organ and system damage occurs due to electron snatching

Engineering Contradiction:
Improvemetabolic processesVSAvoidfree radical damage
Core Design Contradiction:
Use of energy by moving objectVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of free radicals into a beneficial outcome by introducing antioxidative ingredients that specifically target and neutralize free radicals. The antioxidative substances (vitamin C, vitamin E, lutein, etc.) donate electrons to free radicals, converting these harmful reactive species into stable molecules, thereby protecting corneal epithelial cells while maintaining normal metabolic processes.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The ophthalmic product effectively prevents eye diseases like ocular inflammation, relieves discomfort, and maintains eye health by providing antioxidative and anti-inflammatory effects through the synergistic action of gold nanoparticles and auxiliary ingredients, ensuring the eyes remain healthy and comfortable.

Implementation Method 1

unstable free radicals, resulted from internal and external factors, constantly snatch electrons, leading to damage to organs and systems

Methodology Applied
Scientific EffectAntioxidative effect: Redox Reactions

Implementation Method 2

Prolonged exposure to blue light may result in the damage or death of cornea cells... the antioxidative activities of the eye surface areas resulted from Examples 1-4 are better than the antioxidative activity of the eye surface area resulted from Comparative Example 1

Methodology Applied
Scientific EffectOptical absorption: Absorption (EM radiation)

Data Source

PatentEP3756697A1Ophthalmic product with antioxidative function
Publication Date: 2020.12.30 PEGAVISION CORP
  • EP3756697A1 patent drawingFigure 1
  • EP3756697A1 patent drawingFigure 2
  • EP3756697A1 patent drawingFigure 3

AI summary

An ophthalmic product (300, 400) having an antioxidative function includes an ophthalmic composition. The ophthalmic composition includes gold nanoparticles (100) and at least one antioxidative auxiliary ingredient. An effective concentration of the gold nanoparticles (100) is from 0.01 ppm to 3000 ppm. The content of the at least one antioxidative auxiliary ingredient is greater than 0 wt % and less than 20 wt % based on 100 wt % of the ophthalmic composition.